ticlopidine has been researched along with Atherosclerosis in 88 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 9.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| "A total of 574 patients with LAA stroke were randomly assigned to receive either dual therapy or aspirin alone (monotherapy)." | 9.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| "We performed a prospective, randomized, controlled study to compare the combination of esomeprazole and clopidogrel vs clopidogrel alone in preventing recurrent peptic ulcers in patients with atherosclerosis and a history of peptic ulcers." | 9.15 | Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. ( Hsu, PI; Lai, KH; Liu, CP, 2011) |
| "Patients (n = 200) with atherosclerosis were randomized to receive AZD6140 50, 100, or 200 mg twice daily (bid) or 400 mg daily (qd) or clopidogrel 75 mg qd for 28 days." | 9.12 | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. ( Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M, 2006) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 8.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "The anti-platelet drug clopidogrel has been shown to modulate adhesion molecule and cytokine expression, both playing an important role in the pathogenesis of atherosclerosis." | 7.83 | Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. ( Ensminger, SM; Gebhardt, J; Heim, C; Jacobi, J; Ramsperger-Gleixner, M; Weyand, M, 2016) |
| " In this study we investigated the potential of anti-inflammatory (atorvastatin, CD40L knockout) and anti-thrombotic (clopidogrel) intervention strategies to inhibit radiation-induced atherosclerosis." | 7.77 | Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. ( Daemen, MJ; Gabriels, K; Gijbels, MJ; Heeneman, S; Hoving, S; Pol, JF; Russell, NS; Stewart, FA; te Poele, JA, 2011) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 7.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "Aspirin and clopidogrel inhibit neointimal proliferation and prevent the development of atherosclerosis with equivalent effects." | 7.73 | [Inhibitory effects of aspirin, clopidogrel, and their combination on the progression of atherosclerosis in rabbits]. ( Chen, JL; Gu, Q; Ruan, YM, 2005) |
| "Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrombotic events." | 6.74 | PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. ( Cable, G; Willerson, JT; Yeh, ET, 2009) |
| "Atherosclerosis is an inflammatory response of the arterial wall to 'injury', which is prominently driven by inflammatory factors." | 5.34 | Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. ( Li, M; Ren, H; Zhang, Y; Zhu, X, 2007) |
| "From January 2012 to 2016, long-termed thienopyridine users with a peptic ulcer history who did not have peptic ulcers at initial endoscopy were randomly assigned to receive either famotidine (40 mg, before bedtime) or placebo (before bedtime) for 6 months." | 5.24 | Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. ( Chen, WC; Cheng, JS; Hsu, PI; Kao, SS; Lai, KH; Liu, CP; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC, 2017) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 5.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| "A total of 574 patients with LAA stroke were randomly assigned to receive either dual therapy or aspirin alone (monotherapy)." | 5.20 | Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke. ( Chi, L; Liao, D; Lin, J; Wang, C; Yi, X; Zhang, B, 2015) |
| "We analyzed MRI of 133 patients admitted consecutively for intra- and extracranial stenting for symptomatic large artery atherosclerosis who received aspirin and clopidogrel." | 5.16 | Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention. ( Abrigo, J; Ahuja, AT; Leung, TW; Ng, N; Siu, DY; Soo, YO; Wong, LK; Yu, S, 2012) |
| "We performed a prospective, randomized, controlled study to compare the combination of esomeprazole and clopidogrel vs clopidogrel alone in preventing recurrent peptic ulcers in patients with atherosclerosis and a history of peptic ulcers." | 5.15 | Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. ( Hsu, PI; Lai, KH; Liu, CP, 2011) |
| "Patients (n = 200) with atherosclerosis were randomized to receive AZD6140 50, 100, or 200 mg twice daily (bid) or 400 mg daily (qd) or clopidogrel 75 mg qd for 28 days." | 5.12 | Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. ( Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M, 2006) |
| "The safety and efficacy of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in the setting of secondary stroke prevention are reviewed." | 4.91 | Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. ( Davis, KA; Dietrich, E; Miyares, MA, 2015) |
| "The use of aspirin is considered the "gold standard" for the decrease of major adverse cardiovascular events in patients with atherosclerosis, including peripheral arterial disease (PAD), whereas a dual-antiplatelet regimen with aspirin and clopidogrel is usually indicated for such patients after angioplasty and stent deployment." | 4.90 | High on-treatment platelet reactivity in peripheral endovascular procedures. ( Hatzidakis, A; Kassimis, G; Krokidis, M; Spiliopoulos, S, 2014) |
| "Recent trials of antiplatelet therapy for stroke prevention indicate that the combination of clopidogrel (75 mg/d) plus low-dose aspirin (75-162 mg/d) was not more effective than low-dose aspirin alone in the long-term prevention of major vascular events among patients at high risk of atherothrombotic events, nor was it more effective than oral anticoagulation in patients with atrial fibrillation." | 4.84 | Antiplatelet therapy for stroke prevention. ( Hankey, GJ, 2007) |
| "The long-awaited results of the Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack (MATCH) study, a large-scale trial undertaken to evaluate the safety and efficacy of clopidogrel + aspirin for secondary prevention of stroke, have been published." | 4.83 | MATCH results: implications for the internist. ( Lutsep, HL, 2006) |
| "The current standard of care for the treatment of arterial thrombosis includes anticoagulants and three classes of antiplatelet agents--aspirin, thienopyridines and glycoprotein IIb-IIIa antagonists." | 4.82 | Therapeutic approaches in arterial thrombosis. ( Andre, P; Conley, PB; Phillips, DR; Sinha, U, 2005) |
| "The anti-platelet drug clopidogrel has been shown to modulate adhesion molecule and cytokine expression, both playing an important role in the pathogenesis of atherosclerosis." | 3.83 | Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. ( Ensminger, SM; Gebhardt, J; Heim, C; Jacobi, J; Ramsperger-Gleixner, M; Weyand, M, 2016) |
| " Ticagrelor and clopidogrel effectively reduced platelet reactivity but were unable to inhibit early atherogenesis, demonstrating that these P2Y12 inhibitors may not be effective in preventing early disease." | 3.80 | Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. ( Francis, SE; Judge, HM; Steiner, T; Storey, RF; West, LE, 2014) |
| "To evaluate the effect of clopidogrel on atherosclerosis progression." | 3.79 | Antiatherosclerotic potential of clopidogrel: antioxidant and anti-inflammatory approaches. ( Ajeena, IM; Hadi, NR; Mohammad, BI; Sahib, HH, 2013) |
| " In this study we investigated the potential of anti-inflammatory (atorvastatin, CD40L knockout) and anti-thrombotic (clopidogrel) intervention strategies to inhibit radiation-induced atherosclerosis." | 3.77 | Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice. ( Daemen, MJ; Gabriels, K; Gijbels, MJ; Heeneman, S; Hoving, S; Pol, JF; Russell, NS; Stewart, FA; te Poele, JA, 2011) |
| "Clopidogrel is a widely used anti-thrombotic for the prevention of stent thrombosis and cardiovascular events in patients with coronary atherosclerosis." | 3.75 | Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. ( Afek, A; George, J; Keren, G; Kogan, E; Maysel-Auslender, S; Mor, A; Regev, E; Rubinstein, A, 2009) |
| "To model the 2-year cost-effectiveness of secondary prevention with clopidogrel versus aspirin (acetylsalicylic acid) (ASS) in German patients with myocardial infarction (MI), ischaemic stroke (IS) or diagnosed with peripheral arterial disease (PAD), based on CAPRIE trial data and from the perspective of German third party payers (TPP)." | 3.74 | Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. ( Berger, K; Diener, HC; Hessel, F; Kreuzer, J; Smala, A, 2008) |
| "Acetylsalicylic acid (ASA) and the thienopyridine clopidogrel are established anti-platelet drugs that significantly reduce secondary cardiovascular events in patients with manifest atherosclerosis." | 3.74 | Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. ( Koellnberger, M; Konrad, I; Lorenz, R; Massberg, S; Orschiedt, L; Sauer, S; Schulz, C; Walter, U, 2008) |
| "Aspirin and clopidogrel inhibit neointimal proliferation and prevent the development of atherosclerosis with equivalent effects." | 3.73 | [Inhibitory effects of aspirin, clopidogrel, and their combination on the progression of atherosclerosis in rabbits]. ( Chen, JL; Gu, Q; Ruan, YM, 2005) |
| "Metabolic syndrome is associated with intravascular inflammation, as determined by increased levels of inflammatory biomarkers and an increased risk of ischemic atherothrombotic events." | 2.74 | PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. ( Cable, G; Willerson, JT; Yeh, ET, 2009) |
| "Ticagrelor treatment was well tolerated in DISPERSE-2, and discontinuation rates were comparable to those observed for clopidogrel." | 2.45 | Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. ( Husted, S; van Giezen, JJ, 2009) |
| " Currently, efficiency, dosing and indications of established antiplatelet substances are being re-evaluated, whilst new, so far unrecognized molecular targets for inhibition of platelet activity come up front." | 2.44 | Antiplatelet drugs in cardiological practice: established strategies and new developments. ( Klauss, V; Krötz, F; Sohn, HY, 2008) |
| "Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system." | 2.44 | Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007) |
| "As well as initiating thrombus formation at the site of a ruptured atherosclerotic plaque, platelets play a key role in vascular inflammation, through release of their own pro-inflammatory mediators and interactions with other relevant cell types (endothelial cells, leukocytes, and smooth muscle cells)." | 2.44 | Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. ( Badimon, JJ; Bhatt, DL; Herbert, JM; Lüscher, TF; Steinhubl, SR, 2007) |
| "Atherothrombosis is a generalized and progressive process with an inflammatory component." | 2.44 | Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients. ( Ellahham, S, 2008) |
| "Fibrinogen level was altered by adding to blood samples 1/10 volume of fibrinogen solution (10." | 1.43 | Effect of Fibrinogen on Platelet Reactivity Measured by the VerifyNow P2Y12 Assay. ( Dobrovolsky, AB; Guskova, EV; Laguta, PS; Panchenko, EP; Storozhilova, AN; Titaeva, EV; Yarovaya, EB, 2016) |
| "Smokers have a greater relative benefit of clopidogrel therapy compared with nonsmokers, likely attributed to its enhanced pharmacodynamic (PD) effects." | 1.40 | Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. ( Angiolillo, DJ; Bass, TA; Bhatti, M; Cho, JR; Darlington, A; Degroat, C; Desai, B; Ferrante, E; Ferreiro, J; Franchi, F; Guzman, LA; Muniz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM, 2014) |
| "Atherosclerosis is considered as a moderate systemic inflammation and we hypothesise that this chronic condition could have an impact on the outcome in sepsis." | 1.39 | Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. ( Boettel, J; Breuel, H; Kabisch, B; Lösche, W; Otto, GP; Sossdorf, M; Winning, J, 2013) |
| "We describe a patient with terminal renal cell carcinoma who developed late iliac artery stent thrombosis despite dual chronic antiplatelet therapy with aspirin and clopidogrel." | 1.36 | Late common iliac artery stent thrombosis in a patient with terminal malignancy. ( Akgün, T; Can, MM; Karabay, CY; Kaymaz, C; Ozveren, O; Serebruany, V; Tanboğa, IH; Tokgöz, HC; Türkyilmaz, E, 2010) |
| "Clopidogrel has been used to treat atherosclerosis; however, the mechanism is not entirely known." | 1.36 | Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model. ( Feng, L; Jiang, J; Li, M; Ren, H; Zhang, Y; Zhu, X, 2010) |
| "Only atorvastatin treatment did not show any histological atheroprotective effect." | 1.35 | Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats. ( Annapurna, A; Reddy, YN; Srinivas, M, 2008) |
| "Isolated splenic infarction as a complication of the procedure is extreme rare." | 1.35 | Athero-embolic isolated splenic infarction following left cardiac catheterization. ( Hussein, A; Irani, F; Kasmani, R; Mohan, G, 2009) |
| "Atherosclerosis is an inflammatory response of the arterial wall to 'injury', which is prominently driven by inflammatory factors." | 1.34 | Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. ( Li, M; Ren, H; Zhang, Y; Zhu, X, 2007) |
| "Aspirin was given starting 3 days before the intervention and administered for an additional 4 weeks." | 1.33 | Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs. ( Claussen, CD; Dinkelborg, LM; Duda, SH; Laule, M; Muschick, P; Reddig, F; Tepe, G; Tielemans, H; Wehrmann, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 43 (48.86) | 29.6817 |
| 2010's | 42 (47.73) | 24.3611 |
| 2020's | 3 (3.41) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, J | 1 |
| Xu, X | 1 |
| Wang, H | 1 |
| He, L | 1 |
| Liu, Q | 1 |
| Du, Y | 1 |
| Wang, J | 1 |
| Girotra, S | 1 |
| Stebbins, A | 1 |
| Wruck, L | 1 |
| Marquis-Gravel, G | 1 |
| Gupta, K | 1 |
| Farrehi, P | 1 |
| Benziger, CP | 1 |
| Effron, MB | 1 |
| Whittle, J | 1 |
| Muñoz, D | 1 |
| Kripalani, S | 1 |
| Anderson, RD | 1 |
| Jain, SK | 1 |
| Polonsky, TS | 1 |
| Ahmad, FS | 1 |
| Roe, MT | 1 |
| Rothman, RL | 1 |
| Harrington, RA | 1 |
| Hernandez, AF | 1 |
| Jones, WS | 1 |
| Chiarito, M | 1 |
| Sanz-Sánchez, J | 1 |
| Cannata, F | 1 |
| Cao, D | 1 |
| Sturla, M | 1 |
| Panico, C | 1 |
| Godino, C | 1 |
| Regazzoli, D | 1 |
| Reimers, B | 1 |
| De Caterina, R | 1 |
| Condorelli, G | 1 |
| Ferrante, G | 1 |
| Stefanini, GG | 1 |
| Vogel, B | 1 |
| Baber, U | 1 |
| Theidel, U | 1 |
| Asseburg, C | 1 |
| Giannitsis, E | 1 |
| Katus, H | 1 |
| Spiliopoulos, S | 1 |
| Kassimis, G | 1 |
| Hatzidakis, A | 1 |
| Krokidis, M | 1 |
| Acharji, S | 1 |
| Lakshmanadoss, U | 1 |
| Rudzinski, W | 1 |
| Stapleton, DD | 1 |
| Kaluski, E | 1 |
| Ferreiro, JL | 2 |
| Bhatt, DL | 8 |
| Ueno, M | 1 |
| Bauer, D | 1 |
| Angiolillo, DJ | 3 |
| Rollini, F | 1 |
| Franchi, F | 1 |
| Cho, JR | 1 |
| Degroat, C | 1 |
| Bhatti, M | 1 |
| Ferrante, E | 1 |
| Patel, R | 1 |
| Darlington, A | 1 |
| Tello-Montoliu, A | 1 |
| Desai, B | 1 |
| Ferreiro, J | 1 |
| Muniz-Lozano, A | 1 |
| Zenni, MM | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Hadi, NR | 1 |
| Mohammad, BI | 1 |
| Ajeena, IM | 1 |
| Sahib, HH | 1 |
| West, LE | 1 |
| Steiner, T | 1 |
| Judge, HM | 1 |
| Francis, SE | 1 |
| Storey, RF | 2 |
| Gremmel, T | 1 |
| Durstberger, M | 1 |
| Eichelberger, B | 1 |
| Koppensteiner, R | 1 |
| Kopp, CW | 1 |
| Panzer, S | 1 |
| Koziolova, NA | 1 |
| Kuramitsu, S | 1 |
| Sonoda, S | 1 |
| Yokoi, H | 1 |
| Iwabuchi, M | 1 |
| Nishizaki, Y | 1 |
| Shinozaki, T | 1 |
| Domei, T | 1 |
| Hyodo, M | 1 |
| Inoue, K | 1 |
| Shirai, S | 1 |
| Ando, K | 1 |
| Nobuyoshi, M | 1 |
| Wang, C | 1 |
| Yi, X | 1 |
| Zhang, B | 1 |
| Liao, D | 1 |
| Lin, J | 1 |
| Chi, L | 1 |
| Heim, C | 1 |
| Gebhardt, J | 1 |
| Ramsperger-Gleixner, M | 1 |
| Jacobi, J | 1 |
| Weyand, M | 1 |
| Ensminger, SM | 1 |
| Davis, KA | 1 |
| Miyares, MA | 1 |
| Dietrich, E | 1 |
| Dobrovolsky, AB | 1 |
| Laguta, PS | 1 |
| Guskova, EV | 1 |
| Yarovaya, EB | 1 |
| Titaeva, EV | 1 |
| Storozhilova, AN | 1 |
| Panchenko, EP | 1 |
| Hong, KS | 1 |
| Lee, SH | 1 |
| Kim, EG | 1 |
| Cho, KH | 1 |
| Chang, DI | 1 |
| Rha, JH | 1 |
| Bae, HJ | 1 |
| Lee, KB | 1 |
| Kim, DE | 1 |
| Park, JM | 1 |
| Kim, HY | 1 |
| Cha, JK | 1 |
| Yu, KH | 1 |
| Lee, YS | 1 |
| Lee, SJ | 1 |
| Choi, JC | 1 |
| Cho, YJ | 1 |
| Kwon, SU | 2 |
| Kim, GM | 1 |
| Sohn, SI | 1 |
| Park, KY | 1 |
| Kang, DW | 2 |
| Sohn, CH | 1 |
| Lee, J | 1 |
| Yoon, BW | 1 |
| Díaz-Villamarín, X | 1 |
| Dávila-Fajardo, CL | 1 |
| Martínez-González, LJ | 1 |
| Carmona-Sáez, P | 1 |
| Sánchez-Ramos, J | 1 |
| Álvarez Cubero, MJ | 1 |
| Salmerón-Febres, LM | 1 |
| Cabeza Barrera, J | 1 |
| Fernández-Quesada, F | 1 |
| Hsu, PI | 2 |
| Wu, DC | 1 |
| Tsay, FW | 1 |
| Cheng, JS | 1 |
| Liu, CP | 2 |
| Lai, KH | 2 |
| Chen, WC | 1 |
| Wang, HM | 1 |
| Tsai, TJ | 1 |
| Tsai, KW | 1 |
| Kao, SS | 1 |
| Zimmermann, N | 1 |
| Hohlfeld, T | 1 |
| Krötz, F | 1 |
| Sohn, HY | 1 |
| Klauss, V | 1 |
| Srinivas, M | 1 |
| Annapurna, A | 1 |
| Reddy, YN | 1 |
| Mohler, ER | 1 |
| Faxon, DP | 1 |
| Freedman, JE | 1 |
| Hussein, A | 1 |
| Kasmani, R | 1 |
| Irani, F | 1 |
| Mohan, G | 1 |
| Afek, A | 1 |
| Kogan, E | 1 |
| Maysel-Auslender, S | 1 |
| Mor, A | 1 |
| Regev, E | 1 |
| Rubinstein, A | 1 |
| Keren, G | 1 |
| George, J | 1 |
| Mak, KH | 4 |
| Shao, M | 2 |
| Hankey, GJ | 3 |
| Easton, JD | 1 |
| Fox, KA | 5 |
| Topol, EJ | 5 |
| Biller, J | 1 |
| Spinler, SA | 1 |
| Rees, C | 1 |
| Alban, S | 1 |
| Dingermann, T | 1 |
| Husted, S | 3 |
| van Giezen, JJ | 1 |
| Melissa Thornton, S | 1 |
| Lawrance, R | 1 |
| Wickens, M | 2 |
| Emanuelsson, H | 2 |
| Cannon, CP | 1 |
| Heptinstall, S | 2 |
| Armstrong, M | 1 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Willerson, JT | 1 |
| Cable, G | 1 |
| Yeh, ET | 1 |
| Gurbel, PA | 2 |
| Tantry, US | 2 |
| Ren, H | 2 |
| Li, M | 2 |
| Feng, L | 1 |
| Jiang, J | 1 |
| Zhang, Y | 4 |
| Zhu, X | 2 |
| Can, MM | 1 |
| Tanboğa, IH | 1 |
| Ozveren, O | 1 |
| Karabay, CY | 1 |
| Akgün, T | 1 |
| Türkyilmaz, E | 1 |
| Tokgöz, HC | 1 |
| Kaymaz, C | 1 |
| Serebruany, V | 1 |
| Logman, JF | 1 |
| Heeg, BM | 1 |
| Herlitz, J | 1 |
| van Hout, BA | 1 |
| Givol, N | 1 |
| Halkin, A | 1 |
| Laine, L | 1 |
| Schmidt, M | 1 |
| Riis, AH | 1 |
| Christiansen, CF | 1 |
| Lash, TL | 1 |
| Sørensen, HT | 1 |
| Weber, M | 1 |
| Brennan, DM | 2 |
| Steinhubl, SR | 5 |
| Johnston, SC | 1 |
| Montalescot, G | 4 |
| Easton, DJ | 1 |
| Hamm, CW | 1 |
| Breet, NJ | 1 |
| van Werkum, JW | 1 |
| Bouman, HJ | 1 |
| Kelder, JC | 1 |
| Harmsze, AM | 1 |
| Hackeng, CM | 1 |
| ten Berg, JM | 1 |
| Madsen, EH | 1 |
| Gehr, NR | 1 |
| Johannesen, NL | 1 |
| Schmidt, EB | 1 |
| Kristensen, SR | 1 |
| Takeda, M | 1 |
| Yamashita, T | 1 |
| Shinohara, M | 1 |
| Sasaki, N | 1 |
| Tawa, H | 1 |
| Nakajima, K | 1 |
| Momose, A | 1 |
| Hirata, K | 1 |
| Berger, JS | 1 |
| Steg, PG | 3 |
| Hacke, W | 3 |
| Berger, PB | 2 |
| Lincoff, AM | 2 |
| Khemasuwan, D | 1 |
| Chae, YK | 1 |
| Gupta, S | 1 |
| Carpio, A | 1 |
| Yun, JH | 1 |
| Neagu, S | 1 |
| Lucca, AB | 1 |
| Valsecchi, ME | 1 |
| Mora, JI | 1 |
| Hoving, S | 1 |
| Heeneman, S | 1 |
| Gijbels, MJ | 1 |
| te Poele, JA | 1 |
| Pol, JF | 1 |
| Gabriels, K | 1 |
| Russell, NS | 1 |
| Daemen, MJ | 1 |
| Stewart, FA | 1 |
| Blache, D | 1 |
| Gautier, T | 1 |
| Tietge, UJ | 1 |
| Lagrost, L | 1 |
| Jeong, YH | 1 |
| Park, Y | 1 |
| Bliden, KP | 1 |
| Chatterjee, S | 1 |
| Maitra, S | 1 |
| Chakraborty, A | 1 |
| Kim, BJ | 1 |
| Lee, SW | 1 |
| Park, SW | 1 |
| Kim, JS | 1 |
| Paré, G | 1 |
| Eikelboom, JW | 1 |
| Simonsen, KL | 1 |
| Emison, ES | 1 |
| Bhakta, N | 1 |
| Flather, MD | 2 |
| Cacoub, P | 1 |
| Creager, MA | 1 |
| Murugesan, G | 1 |
| Mehta, SR | 1 |
| Kottke-Marchant, K | 1 |
| Soo, YO | 1 |
| Siu, DY | 1 |
| Abrigo, J | 1 |
| Yu, S | 1 |
| Ng, N | 1 |
| Ahuja, AT | 1 |
| Wong, LK | 1 |
| Leung, TW | 1 |
| Kourlaba, G | 1 |
| Fragoulakis, V | 1 |
| Maniadakis, N | 1 |
| Reinhart, WH | 1 |
| Otto, GP | 1 |
| Sossdorf, M | 1 |
| Boettel, J | 1 |
| Kabisch, B | 1 |
| Breuel, H | 1 |
| Winning, J | 1 |
| Lösche, W | 1 |
| Gu, Q | 1 |
| Chen, JL | 1 |
| Ruan, YM | 1 |
| Phillips, DR | 1 |
| Conley, PB | 1 |
| Sinha, U | 1 |
| Andre, P | 1 |
| Tepe, G | 1 |
| Muschick, P | 1 |
| Laule, M | 1 |
| Reddig, F | 1 |
| Claussen, CD | 1 |
| Dinkelborg, LM | 1 |
| Tielemans, H | 1 |
| Wehrmann, M | 1 |
| Duda, SH | 1 |
| Sandset, PM | 1 |
| Peters, G | 1 |
| Defuentes, G | 1 |
| Lecoules, S | 1 |
| Vedrine, L | 1 |
| Coutant, G | 1 |
| Baranger, B | 1 |
| Algayres, JP | 1 |
| Hiatt, WR | 1 |
| Krantz, MJ | 1 |
| Lutsep, HL | 1 |
| Casella, G | 1 |
| Greco, C | 1 |
| Perugini, E | 1 |
| Pallotti, MG | 1 |
| Pavesi, PC | 1 |
| Di Pasquale, G | 1 |
| Amarenco, P | 1 |
| Röther, J | 1 |
| Michel, P | 1 |
| Davis, SM | 1 |
| Donnan, GA | 1 |
| Norris, JW | 1 |
| Barnett, HJ | 1 |
| Liao, JK | 1 |
| Maree, AO | 1 |
| Fitzgerald, DJ | 1 |
| Meadows, TA | 1 |
| Kikano, GE | 1 |
| Brown, MT | 1 |
| Badimon, JJ | 1 |
| Herbert, JM | 1 |
| Lüscher, TF | 1 |
| Anand, S | 1 |
| Yusuf, S | 1 |
| Xie, C | 1 |
| Pogue, J | 1 |
| Eikelboom, J | 1 |
| Budaj, A | 1 |
| Sussex, B | 1 |
| Liu, L | 1 |
| Guzman, R | 1 |
| Cina, C | 1 |
| Crowell, R | 1 |
| Keltai, M | 1 |
| Gosselin, G | 1 |
| Wang, TH | 1 |
| Pearson, TA | 1 |
| Boden, WE | 1 |
| Fisher, M | 1 |
| Johns, T | 1 |
| Zatevakhin, II | 1 |
| Zolkin, VN | 1 |
| Shiller, EE | 1 |
| Berger, K | 1 |
| Hessel, F | 1 |
| Kreuzer, J | 1 |
| Smala, A | 1 |
| Diener, HC | 1 |
| Schulz, C | 1 |
| Konrad, I | 1 |
| Sauer, S | 1 |
| Orschiedt, L | 1 |
| Koellnberger, M | 1 |
| Lorenz, R | 1 |
| Walter, U | 1 |
| Massberg, S | 1 |
| Ellahham, S | 1 |
| Comerota, AJ | 1 |
| Thakur, S | 1 |
| Kapoor, JR | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial[NCT00814268] | Phase 4 | 358 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer and Gastrointestinal Bleeding[NCT01138969] | Phase 2 | 165 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558] | Phase 3 | 90 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| A Phase III Randomized Trial of Warfarin Plus Antiplatelet Therapy Versus Antiplatelet Therapy Alone in Patients With Peripheral Vascular Disease[NCT00125671] | Phase 3 | 2,400 participants | Interventional | 2000-01-31 | Active, not recruiting | ||
| Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-01-09 | Recruiting | ||
| DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656] | Phase 4 | 159 participants (Actual) | Interventional | 2020-06-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
participants with peptic ulcer bleeding within 6 months (NCT01138969)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Plus Clopidogrel Group | 0 |
| Clopidogrel Group | 1 |
Number of participants with recurrent peptic ulcer within 6 months (NCT01138969)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Esomeprazole Plus Clopidogrel Group | 1 |
| Clopidogrel Group | 9 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
28 reviews available for ticlopidine and Atherosclerosis
| Article | Year |
|---|---|
Monotherapy with a P2Y
Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He | 2020 |
Antiplatelet treatments: recent evidence from randomized controlled trials.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Atherosclerosis; Blood Platelets; Humans; Platelet Aggr | 2017 |
High on-treatment platelet reactivity in peripheral endovascular procedures.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Endovascular Procedures; Humans; Peripheral | 2014 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Dis | 2013 |
[Antiplatelet therapy in atherosclerosis of various localizations: acute and stable States].
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Drug Therapy, Combination; Drug-Related Side Effe | 2014 |
Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic | 2015 |
Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.
Topics: Aged; Angioplasty; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cyto | 2016 |
Clinical implications of aspirin resistance.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Drug Resistance; | 2008 |
Antiplatelet drugs in cardiological practice: established strategies and new developments.
Topics: Atherosclerosis; Clopidogrel; Drug-Eluting Stents; Humans; Piperazines; Platelet Activation; Platele | 2008 |
Combination antiplatelet therapy in patients with peripheral arterial disease: is the best therapy aspirin, clopidogrel, or both?
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Evidence-Based Me | 2009 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Review of prasugrel for the secondary prevention of atherothrombosis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Clopidogrel; Humans; Piper | 2009 |
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Animals; Atherosclerosis; Clinical Trials | 2009 |
Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions.
Topics: Atherosclerosis; Clopidogrel; Forecasting; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Re | 2010 |
Combination antithrombotic therapies.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Pyrid | 2010 |
Therapeutic approaches in arterial thrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atherosclerosis; Blood Pl | 2005 |
Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Intermittent Claudication; | 2006 |
MATCH results: implications for the internist.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Controlled Clinical Trials as Topic; Double-Blind Method; Dru | 2006 |
[Atheromatosis of the thoracic aorta and risk of stroke].
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Atherosclerosis; Clopidogrel; Controlled | 2006 |
Aortic arch atheroma and the risk of stroke.
Topics: Aorta, Thoracic; Aspirin; Atherosclerosis; Clopidogrel; History, 18th Century; Humans; Risk Factors; | 2006 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Variable platelet response to aspirin and clopidogrel in atherothrombotic disease.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers | 2007 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyrid | 2007 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.
Topics: Angina, Unstable; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Humans; Inflam | 2007 |
Antiplatelet therapy for stroke prevention.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel | 2007 |
Role of antiplatelet agents in the primary and secondary prevention of atherothrombotic events in high risk-patients.
Topics: Aspirin; Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; D | 2008 |
Antiplatelet therapy for vascular interventions.
Topics: Angioplasty, Balloon; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Endarterecto | 2008 |
20 trials available for ticlopidine and Atherosclerosis
| Article | Year |
|---|---|
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage; | 2023 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Deci | 2013 |
Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events).
Topics: Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Female; Humans; Male; Risk Factors; Single-Bl | 2014 |
Clopidogrel plus aspirin prevents early neurologic deterioration and improves 6-month outcome in patients with acute large artery atherosclerosis stroke.
Topics: Acute Disease; Aged; Aspirin; Atherosclerosis; Clopidogrel; Female; Humans; Male; Nervous System Dis | 2015 |
Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone.
Topics: Aged; Aspirin; Atherosclerosis; Brain; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therap | 2016 |
Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atherosclerosis; Clopidogrel; Double-Blind Method; F | 2017 |
Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study.
Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Double-Blind Method; Ethnicity; Female; Follow-U | 2009 |
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
Topics: Adenosine; Adenosine Diphosphate; Area Under Curve; Atherosclerosis; Clopidogrel; Dose-Response Rela | 2009 |
PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Biomarkers; C-Re | 2009 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis.
Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-4 | 2011 |
High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clopidogrel | 2011 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati | 2011 |
Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis.
Topics: Aged; Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Pla | 2011 |
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Aged; Atherosclerosis; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind M | 2011 |
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study.
Topics: Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genot | 2012 |
Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; | 2012 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding | 2006 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Aspirin; Atherosclerosis; Cardiovascular Diseas | 2007 |
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Topics: Aged; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Disease-Free Survival; Drug Th | 2007 |
[The assessment of TIKLO efficacy in patients with intermittent claudication].
Topics: Aged; Atherosclerosis; Exercise Test; Female; Humans; Intermittent Claudication; Lower Extremity; Ma | 2007 |
40 other studies available for ticlopidine and Atherosclerosis
| Article | Year |
|---|---|
Dual Antiplatelet Therapy Plus Argatroban Prevents Early Neurological Deterioration in Branch Atherosclerosis Disease.
Topics: Arginine; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Humans; Pipecolic Acids; Platelet A | 2022 |
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Topics: Adult; Aged; Aspirin; Atherosclerosis; Biomarkers; Blood Platelets; Clopidogrel; Cotinine; Female; F | 2014 |
Antiatherosclerotic potential of clopidogrel: antioxidant and anti-inflammatory approaches.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atherosclerosis; Chemokine CCL2; Clopidogrel; Gene | 2013 |
Vessel wall, not platelet, P2Y12 potentiates early atherogenesis.
Topics: Adenosine; Animals; Apolipoproteins E; Atherosclerosis; Blood Platelets; Blood Vessels; Clopidogrel; | 2014 |
Human neutrophil α-defensins are associated with adenosine diphosphate-inducible neutrophil-platelet aggregate formation and response to clopidogrel in patients with atherosclerosis.
Topics: Adenosine Diphosphate; alpha-Defensins; Atherosclerosis; C-Reactive Protein; Clopidogrel; Flow Cytom | 2014 |
Long-term coronary arterial response to biodegradable polymer biolimus-eluting stents in comparison with durable polymer sirolimus-eluting stents and bare-metal stents: five-year follow-up optical coherence tomography study.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Atherosclerosis; Coronary Angiography; Coronary Vessel | 2014 |
Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Biomarkers; Chemokine | 2016 |
Effect of Fibrinogen on Platelet Reactivity Measured by the VerifyNow P2Y12 Assay.
Topics: Atherosclerosis; Blood Platelets; Clopidogrel; Fibrinogen; Humans; Immobilized Proteins; Nephelometr | 2016 |
Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats.
Topics: Animals; Atherosclerosis; Atorvastatin; Clopidogrel; Diet, Atherogenic; Drug Interactions; Female; H | 2008 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dos | 2009 |
Athero-embolic isolated splenic infarction following left cardiac catheterization.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Atherosclerosis | 2009 |
Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cell Proliferation; Cells, Cultured; Clopidogrel; Disea | 2009 |
[Pharmazie in unserer Zeit 4/2009].
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation; P | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model.
Topics: Animals; Apoptosis; Atherosclerosis; Atorvastatin; C-Reactive Protein; Catheterization; Clopidogrel; | 2010 |
Late common iliac artery stent thrombosis in a patient with terminal malignancy.
Topics: Aged; Angiography; Aspirin; Atherosclerosis; Carcinoma, Renal Cell; Clopidogrel; Humans; Iliac Arter | 2010 |
Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Topics: Aged; Aspirin; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Markov Cha | 2010 |
[Dental management of patients using anti agregant drugs: background, risks and clinical guidelines].
Topics: Atherosclerosis; Clopidogrel; Dentistry; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practi | 2009 |
Proton pump inhibitor co-therapy with clopidogrel: is there GI benefit or cardiovascular harm?
Topics: Atherosclerosis; Clopidogrel; Drug Interactions; Humans; Omeprazole; Peptic Ulcer; Platelet Aggregat | 2011 |
Clopidogrel use and short-term mortality after peptic ulcer bleeding: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Clopidogrel; Cohort Studies; Denmark; Female; Human | 2013 |
Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Brachiocephalic Trunk; Cell Adhesio | 2012 |
Dose-related effect of statins in venous thrombosis risk reduction.
Topics: Aged; Aspirin; Atherosclerosis; Cerebral Infarction; Clopidogrel; Cohort Studies; Cross-Sectional St | 2011 |
Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Carotid Arterie | 2011 |
Activated platelets contribute to oxidized low-density lipoproteins and dysfunctional high-density lipoproteins through a phospholipase A2-dependent mechanism.
Topics: Animals; Atherosclerosis; Blood Platelets; Enzyme Inhibitors; Female; Group II Phospholipases A2; Hu | 2012 |
High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype.
Topics: Aspirin; Atherosclerosis; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitor | 2012 |
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Topics: Atherosclerosis; Female; Hemorrhage; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibit | 2012 |
Insufficient platelet inhibition is related to silent embolic cerebral infarctions after coronary angiography.
Topics: Aged; Aspirin; Atherosclerosis; Basilar Artery; Carotid Arteries; Cerebral Infarction; Clopidogrel; | 2012 |
Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Greece; Human | 2012 |
Platelets in vascular disease.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Hemostasis; Humans; Plaque, Atherosclerotic; | 2013 |
Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Blood Coagulation; Clopidog | 2013 |
[Inhibitory effects of aspirin, clopidogrel, and their combination on the progression of atherosclerosis in rabbits].
Topics: Animals; Aorta; Aspirin; Atherosclerosis; C-Reactive Protein; Cell Count; Clopidogrel; Cyclooxygenas | 2005 |
Prevention of carotid artery restenosis after sirolimus-coated stent implantation in pigs.
Topics: Alloys; Angioplasty, Balloon, Coronary; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; A | 2006 |
[Accelerated atheroma with prednisone and clopidogrel].
Topics: Aged; Atherosclerosis; Carotid Stenosis; Clopidogrel; Endarterectomy; Giant Cell Arteritis; Glucocor | 2006 |
CHARISMA: the antiplatelet saga continues.
Topics: Atherosclerosis; Clinical Trials as Topic; Clopidogrel; Humans; Ischemia; Platelet Aggregation Inhib | 2006 |
Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model.
Topics: Animals; Aspirin; Atherosclerosis; Atorvastatin; Chemokine CCL2; Clopidogrel; Diet, Atherogenic; Dis | 2007 |
Letter by Fisher and Johns regarding article, "Variable platelet response to aspirin and clopidogrel in atherothrombotic disease".
Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Tab | 2007 |
Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Clopidogrel; Cohort Studies; Coronary Thrombosis; | 2008 |
Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo.
Topics: Animals; Aorta; Apolipoproteins E; Aspirin; Atherosclerosis; Blood Platelets; Carotid Arteries; Chol | 2008 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M | 2008 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |